Exaggerated imiquimod application site reactions in the context of systemic tumor necrosis factor-alpha inhibition: More than a coincidental occurrence?

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 2, 2011, Pages 509-515

  Saggini, Andrea ^a   Saraceno, R ^a   Chimenti, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Adverse drug reaction; Imiquimod; Infliximab; Psoriasis; TNF alpha inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; BISOPROLOL; FLECAINIDE ACETATE; IMIQUIMOD; INFLIXIMAB; LANSOPRAZOLE; METHOTREXATE; ZINC OXIDE; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; BASAL CELL CARCINOMA; CASE REPORT; CLINICAL EVALUATION; DIVERTICULOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIOSIS; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; SCAR FORMATION; SKIN CANCER; TREATMENT OUTCOME; ULCER; CONSERVATIVE TREATMENT; DISEASE COURSE; EPILUMINESCENCE MICROSCOPY; HISTOPATHOLOGY; MALE; MIDDLE AGED; PSORIATIC ARTHRITIS; SKIN ULCER; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG ERUPTION; DRUG INTERACTION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; LETTER; METABOLISM; PATHOLOGY; SKIN TUMOR;

ADMINISTRATION, CUTANEOUS; AGED; AMINOQUINOLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SKIN NEOPLASMS; SKIN ULCER; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; ZINC OXIDE;

EID: 80051768251     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400225     Document Type: Article

References (25)

1. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23:1-70.
2. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009; 61:486-504.
3. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156:486-91.
4. Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61:104-11.
5. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145:1431-8.
6. Gaspari A, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 2009; 8:467-74.
7. Peris K, Micantonio T, Fargnoli MC, Lozzi GP, Chimenti S. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol 2006; 55:324-7. (Pubitemid 44038022)
8. Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005; 31:318-23. (Pubitemid 43072987)
9. Schön MP, Schön M. Imiquimod: mode of action. Br J Dermatol 2007; 157:8-13. (Pubitemid 350179622)
10. Gebauer K, Shumack S, Cowen PS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol 2009; 161:897-903.
11. Altamura D, Menzies SW, Argenziano G, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol 2010; 62:67-75.
12. Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140:1490-5. (Pubitemid 39627441)
13. Charles J, Chaperot L, Salameire D, et al. Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. Eur J Dermatol 2010; 20:16-23.
14. Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009; 29:247-56.
15. Tomasini D, Mentzel T, Hantschke M, et al. Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner's lymphocytic infiltrate of the skin and cutaneous lupus erythematosus. J Cutan Pathol 2010; 37:1132-9.
16. Vermi W, Lonardi S, Morassi M, et al. Cutaneous distribution of plasma cytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology 2009; 214:877-86.
17. Wenzel J, Tüting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis". J Invest Dermatol 2008; 128:2392-402.
18. Barr KL, Konia TH, Fung MA. Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall. J Cutan Pathol DOI: 10.1111/j.1600-0560.2010.01592.x.
19. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009; 20:100-8.
20. Ahdout J, Haley JC, Chiu MW. Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis. J Am Acad Dermatol 2010; 62:874-9.
21. Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009; 161:1081-8.
22. DeGannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143:223-31. (Pubitemid 46294587)
23. Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol 2007; 143:233-6.
24. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005; 102:3372-7. (Pubitemid 40328052)
25. Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis (Review). J Rheumatol DOI: 10.3899/jrheum.100041.